GlaxoSmithKline Offering Free Access to Potential Malaria Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK CEO Andrew Witty is making another push for cooperation in malaria drug research, offering access to 13,500 compounds and the chance for 60 scientists to work at its research centre in Spain.